v3.25.4
Stockholders' equity (Tables)
6 Months Ended
Dec. 31, 2025
Equity [Abstract]  
Schedule of warrants or rights

The activity related to warrants for the six months ended December 31, 2025, is summarized as follows:

 

 

Common
Stock from
Warrants

 

 

Weighted-
average
Exercise
Price (per
share)

 

Outstanding at July 1, 2025

 

 

20,443,496

 

 

$

0.9672

 

Outstanding and exercisable at September 30, 2025

 

 

20,443,496

 

 

$

0.9672

 

Pre-funded warrants exercised

 

 

(200,276

)

 

$

0.0001

 

Series 2 warrants exercised

 

 

(63,792

)

 

$

1.9299

 

Outstanding and exercisable at December 31, 2025

 

 

20,179,428

 

 

$

0.9738

 

Schedule of equity awards

The activity related to equity awards, which are comprised of stock options during the six months ended December 31, 2025 is summarized as follows:

 

 

Stock
Options

 

 

Weighted-
average
Exercise
Price

 

 

Weighted-
average
Remaining
Contractual
Term

 

 

Aggregate
Intrinsic
Value

 

Outstanding at June 30, 2025

 

 

4,902,140

 

 

$

10.81

 

 

9.24 years

 

 

$

7,728,384

 

Granted

 

 

1,956,072

 

 

$

14.24

 

 

9.86 years

 

 

 

 

Forfeited

 

 

(9,215

)

 

$

15.90

 

 

 

 

 

 

 

Outstanding at December 31, 2025

 

 

6,848,997

 

 

$

11.78

 

 

9.05 years

 

 

$

14,822,988

 

Exercisable at December 31, 2025

 

 

1,489,378

 

 

$

11.19

 

 

8.61 years

 

 

$

5,101,825

 

Schedule of share-based compensation expense

The Company estimated the fair value of each employee equity award on the grant date using the Black-Scholes option-pricing model with the following assumptions:

 

 

Six Months Ended

 

 

December 31,

 

 

2025

 

 

2024

 

Expected volatility

 

 

114.7

%

 

 

121.2

%

Expected term

 

6 years

 

 

6 years

 

Risk-free interest rate

 

 

3.78

%

 

 

4.13

%

Expected dividend yield

 

 

%

 

 

%

Schedule of equity-based compensation expense

The classification of share-based compensation expense is summarized as follows:

 

 

Three Months Ended

 

 

Six Months Ended

 

 

December 31,

 

(US$’000)

 

2025

 

 

2024

 

 

2025

 

 

2024

 

Research and development

 

$

2,667

 

 

$

436

 

 

$

3,535

 

 

$

549

 

General and administrative

 

 

4,712

 

 

 

2,702

 

 

 

9,024

 

 

 

3,024

 

Total share-based compensation expense

 

$

7,379

 

 

$

3,138

 

 

$

12,559

 

 

$

3,573